Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Amerikaanse aandelen   /   Hemispherx BioPharma, Inc (Public, AMEX:HEB)

Amerikaanse aandelen« Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

Volgen
13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 | Laatste | Omlaag ↓
  3. [verwijderd] 5 september 2012 17:58
    Allemaal leuk en aardig, maar waar komt stijging vandaan.. gemanipuleer..?

    Voorkennis.... toch opvallend wat laatste weken gebeurd.... kan echt nog een flinke spike komen is mijn verwachting..

    Ik kan buiten bekende nieuws niets vinden.. Speel ook quit nu, maar ja heb r maar 5000..

  11. johnny baboa 3 januari 2013 13:47
    Geachte Heren ,
    Volgens mij is er weer de mogelijkheid om een claim jegens HEB te starten.

    Home
    News Viewer
    Markets
    Investing
    Hedge funds are bullish on these 5 stocks
    Steve Cohen is bullish on Buffalo Wild Wings, while “the Warren Buffett of Canada” takes a contrarian position in SandRidge Energy. Carl Icahn, and Ken Griffin like Take-Two Interactive.
    Billionaire Jeffrey Vinik's cheap stock picks
    Billionaire Jeffrey Vinik returned much of Vinik Asset Management's capital to investors in 2000, but continues to invest money for family and friends. We have already gone through Vinik's most...
    In focus: Back from the brink
    A bullish stance is still warranted overall, even as the bulls have become pigs over the last couple of days.
    Stocks Mutual Funds ETFs Options Bonds Commodities Currencies Futures Hedge Funds/Insider Trades Getting Started MarketWatch Adviser Columns Hulbert on Markets Options Trader Revolution Investing Tools Stock Screener Funds Finder ETF Screener Options Screener More... Trading Deck
    Personal Finance
    Retirement
    Economy/Politics
    Industries
    Log In
    Games
    Alerts
    Portfolio

    press release

    Dec. 28, 2012, 1:00 p.m. EST

    CORRECTING and REPLACING -- SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Hemispherx Biopharma, Inc., and Certain Officers -- HEB

    NEW YORK, Dec 28, 2012 (GLOBE NEWSWIRE via COMTEX) -- In a press release issued December 24, 2012 by Pomerantz Grossman Hufford Dahlstrom & Gross LLP under the same headline, the shareholder deadline to be appointed as Lead Plaintiff was incorrect. Please note that in the second paragraph, the shareholder deadline date should be February 22, 2013, not February 19, 2013, as previously stated.

    The corrected release follows:

    Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") /quotes/zigman/165768/quotes/nls/heb HEB -1.95% and certain of its officers. The class action filed in United States District Court, Eastern District of Pennsylvania, and docketed under 2:12-cv-07152-WY on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Hemispherx between March 19, 2012 and December 17, 2012, both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

    If you are a shareholder who purchased Hemispherx securities during the Class Period, you have until February 22, 2013 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

    Hemispherx is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen(R) ("Ampligen"), is undergoing clinical trials for the treatment of Myalgic Encephalomylitis/Chronic Fatigue Syndrome.

    The Complaint alleges that throughout the Class Period, the Company made a host of materially false and misleading statements regarding the safety and efficacy of Ampligen, and touted purportedly positive results from Ampligen's clinical trials. As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

    On December 18, 2012, the FDA published an FDA staff report concerning Ampligen's safety and efficacy. Specifically, the report concluded that the Company's studies were "ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials, and based on the limited quality of the data, "it is difficult to draw conclusions regarding potential safety signals," but the "review identified nine potential safety concerns associated with Ampligen."

    As a result of this disclosure, Hemispherx shares declined $0.276 per share or nearly 43%, to close at $0.368 per share on December 18, 2012.

    Wat vinden jullie ervan???
    Gr Johnny
  12. johnny baboa 3 januari 2013 16:37
    quote:

    johnny baboa schreef op 3 januari 2013 13:47:

    Geachte Heren ,
    Volgens mij is er weer de mogelijkheid om een claim jegens HEB te starten.


    press release

    Dec. 28, 2012, 1:00 p.m. EST

    CORRECTING and REPLACING -- SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Hemispherx Biopharma, Inc., and Certain Officers -- HEB

    NEW YORK, Dec 28, 2012 (GLOBE NEWSWIRE via COMTEX) -- In a press release issued December 24, 2012 by Pomerantz Grossman Hufford Dahlstrom & Gross LLP under the same headline, the shareholder deadline to be appointed as Lead Plaintiff was incorrect. Please note that in the second paragraph, the shareholder deadline date should be February 22, 2013, not February 19, 2013, as previously stated.

    The corrected release follows:

    Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") /quotes/zigman/165768/quotes/nls/heb HEB -1.95% and certain of its officers. The class action filed in United States District Court, Eastern District of Pennsylvania, and docketed under 2:12-cv-07152-WY on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Hemispherx between March 19, 2012 and December 17, 2012, both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

    If you are a shareholder who purchased Hemispherx securities during the Class Period, you have until February 22, 2013 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

    Hemispherx is a biopharmaceutical company that focuses on the development of nucleic acids to enhance the natural anti-viral defense systems of the human body. The Company's lead product, Ampligen(R) ("Ampligen"), is undergoing clinical trials for the treatment of Myalgic Encephalomylitis/Chronic Fatigue Syndrome.

    The Complaint alleges that throughout the Class Period, the Company made a host of materially false and misleading statements regarding the safety and efficacy of Ampligen, and touted purportedly positive results from Ampligen's clinical trials. As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

    On December 18, 2012, the FDA published an FDA staff report concerning Ampligen's safety and efficacy. Specifically, the report concluded that the Company's studies were "ill-defined and invalid" with signals of efficacy that were inconsistent between clinical trials, and based on the limited quality of the data, "it is difficult to draw conclusions regarding potential safety signals," but the "review identified nine potential safety concerns associated with Ampligen."

    As a result of this disclosure, Hemispherx shares declined $0.276 per share or nearly 43%, to close at $0.368 per share on December 18, 2012.

    Wat vinden jullie ervan???
    Gr Johnny
13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
EBUSCO HOLDING 4,290 +0,74 +20,95%
Aegon 6,162 +0,28 +4,80%
Ahold Delhaize 31,950 +1,12 +3,63%
CM.COM 6,450 +0,16 +2,54%
Galapagos 25,240 +0,54 +2,19%
Akzo Nobel 58,980 +0,90 +1,55%
Air France-KLM 8,872 +0,13 +1,51%
AZERION 1,288 +0,02 +1,42%
BESI 103,100 +1,15 +1,13%
RANDSTAD NV 42,680 +0,45 +1,07%
RELX 44,140 +0,44 +1,01%
Accsys 0,600 +0,01 +0,84%
Wolters Kluwer 160,900 +1,30 +0,81%
TomTom 5,145 +0,04 +0,78%
SBM Offshore 17,180 +0,13 +0,76%
INPOST 17,690 +0,10 +0,57%
ArcelorMittal 23,130 +0,10 +0,43%
Basic-Fit 22,480 +0,08 +0,36%
AMG Critical Materials N.V. 15,510 +0,05 +0,32%
EXOR NV 93,350 +0,30 +0,32%
KPN 3,612 +0,01 +0,25%
Van Lanschot Kempen NV 41,650 +0,10 +0,24%
JUST EAT TAKEAWAY 10,560 +0,03 +0,24%
TKH 36,420 +0,04 +0,11%
SHELL PLC 31,430 +0,02 +0,08%
Fagron 18,700 0,00 0,00%
FASTNED 20,950 0,00 0,00%
Vastned 24,500 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
Alfen N.V. 11,380 -0,75 -6,18%
Sif Holding 13,100 -0,62 -4,52%
CTP 14,540 -0,62 -4,09%
WDP 20,600 -0,84 -3,92%
Pharming 0,724 -0,02 -3,21%
Avantium 2,280 -0,08 -3,18%
ASMI 498,800 -15,60 -3,03%
JDE PEET'S 18,910 -0,58 -2,98%
ING 15,178 -0,44 -2,84%
SIGNIFY NV 21,840 -0,60 -2,67%
Heineken 72,200 -1,84 -2,49%
PROSUS 38,850 -0,98 -2,47%
THEON INTERNAT 8,800 -0,22 -2,44%
Fugro 16,550 -0,39 -2,30%
PostNL 1,013 -0,02 -2,22%
ASML 610,800 -13,20 -2,12%
UNILEVER PLC 55,240 -1,06 -1,88%
Corbion 22,400 -0,40 -1,75%
Arcadis 64,600 -1,10 -1,67%
ADYEN NV 1.376,400 -23,40 -1,67%
DSM FIRMENICH AG 105,400 -1,75 -1,63%
ABN AMRO BANK N.V. 15,130 -0,25 -1,63%
ALLFUNDS GROUP 5,475 -0,09 -1,62%
Sligro 11,100 -0,18 -1,60%
B&S Group SA 4,450 -0,07 -1,55%
NX FILTRATION 4,470 -0,06 -1,32%
Flow Traders 21,380 -0,28 -1,29%
AMX 855,61 -9,85 -1,14%
Eurocommercial Properties 22,900 -0,25 -1,08%
Aperam 25,020 -0,26 -1,03%
RENEWI 7,260 -0,07 -0,95%
ACOMO 17,240 -0,16 -0,92%
ASCX 1.193,16 -11,01 -0,91%
Kendrion 11,000 -0,10 -0,90%
Philips Koninklijke 24,650 -0,21 -0,84%
AEX 875,41 -7,35 -0,83%
Vopak 41,380 -0,34 -0,81%
Wereldhave 14,060 -0,10 -0,71%
NN Group 45,600 -0,31 -0,68%
BAM 4,280 -0,03 -0,65%
NSI 19,400 -0,12 -0,61%
AALBERTS NV 33,100 -0,16 -0,48%
UMG 23,070 -0,09 -0,39%
IMCD 143,900 -0,55 -0,38%
Nedap N.V. 54,400 -0,20 -0,37%
Brunel 8,870 -0,02 -0,22%
HEIJMANS KON 24,600 -0,05 -0,20%
OCI 10,810 -0,02 -0,18%
ForFarmers 3,445 -0,01 -0,14%
ASR Nederland 45,080 -0,05 -0,11%
vlag naam koers verschil relatief verschil
AEX 875,41 -7,35 -0,83%
AEX GR 3.423,21 -28,75 -0,83%
Germany40^ 19.094,60 -161,67 -0,84%
FTSE 100 8.166,68 -5,71 -0,07%
EURO50 4.807,80 -64,72 -1,33%
US30^ 43.755,10 +1.519,30 +3,60%
Nasd100^ 20.783,00 +552,60 +2,73%
US500^ 5.930,03 +144,36 +2,50%
Japan225^ 39.932,40 +960,10 +2,46%
VD-NEW 17,44 -1,26 -6,72%
#/^ Index indications calculated real time, zie disclaimer